C21 Investments Inc

C21 Investments Inc has a current ratio of 0.51, indicating that its current assets are insufficient to cover its current liabilities, which suggests potential liquidity challenges. The company's debt-to-equity ratio is 0.04, reflecting a relatively low level of leverage compared to industry norms. However, the company's free cash flow is negative at -1.53 million USD, which may limit its ability to fund operations or invest in growth without external financing.

The company's profitability is underperforming, with a return on equity of -6.58% and a return on assets of -3.74%, both significantly below the industry median. These metrics suggest that the company is not effectively utilizing its equity or assets to generate returns, which could be a concern for investors.

C21 Investments Inc's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases the company's exposure to regional economic downturns or regulatory changes that could impact its primary market.

The company's growth trajectory is uncertain, with no disclosed revenue growth in the current fiscal year and no clear guidance for the next fiscal year. The negative operating income of -307,660 USD and net loss of -2.04 million USD indicate that the company is currently not generating sufficient revenue to cover its operating expenses.

The company's risk profile includes medium liquidity risk due to its current ratio and negative free cash flow. While dilution risk is currently low, the negative net cash position after subtracting total debt suggests that the company may need to raise additional capital in the future, which could lead to share dilution.

Recent filings and transcripts do not indicate any major strategic shifts or significant operational changes. The company's financial performance remains a key area of focus, with the need to improve profitability and manage liquidity effectively.

Revenue surged 574.5% year-over-year to $30.1 million, demonstrating significant top-line growth momentum in the latest fiscal period.

Operating income increased 342.1% year-over-year to $1.28 million, indicating improved core operational profitability despite net losses.

The debt-to-equity ratio of 0.04 ranks in the above-75th percentile, suggesting a conservative capital structure relative to peers.

Dilution risk is assessed as low, providing some protection for existing shareholders against immediate equity value erosion.

Free cash flow turned negative at -$4.82 million, reversing the positive trend and raising concerns about liquidity generation.

Net margin of -31.2% and operating margin of -4.7% both rank in the bottom quartile of the drug retailer cohort.

Long-term debt increased significantly to $2.84 million in the latest period, up from $1.16 million in the prior year.